RxDoctor Payments Data

Sampathkumar Shanmugham, MD

Neurology · Lake Mary, FLNPI 1053314450

Payments from drug & device makers

$11,767in general payments, 2019–2025

Across 673 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$1K
  • Amgen$499
  • UCB, Inc.$457
  • Lilly USA, LLC$423
  • Acadia Pharmaceuticals Inc$400
  • plus $6K from 53 others

What the payments were for

  • Food & beverage$11,638100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)133$2,085
Novartis128$1,467
Amgen(2 entities)21$499
UCB, Inc.21$457
Lilly USA, LLC23$423
Acadia Pharmaceuticals Inc21$400
Pfizer23$377
Sanofi20$375
Biogen17$332
Amneal Pharmaceuticals LLC16$320
EMD Serono, Inc.22$316
Genentech USA, Inc.15$271
MDD US Operations, LLC19$240
Teva Pharmaceuticals USA, Inc.13$231
Abbott2$227
Biohaven Pharmaceuticals, Inc.17$219
Johnson & Johnson(2 entities)6$211
Adamas Pharmaceuticals, Inc.13$204
Argenx US, Inc.11$202
Lundbeck LLC7$178
Tanabe Pharma America, Inc.9$173
CSL Behring8$170
Bristol Myers Squibb6$160
Eisai Inc.7$150
Alnylam Pharmaceuticals Inc.6$148
GE HealthCare6$142
Otsuka America Pharmaceutical, Inc.7$138
AstraZeneca7$135
Corium, LLC7$126
E.r. Squibb & Sons, L.L.C.1$111
Microvention, Inc.1$108
Biohaven Pharmaceutical Holding Company Ltd.6$103
Mallinckrodt Enterprises LLC4$87
Jazz Pharmaceuticals Inc.4$81
Takeda Pharmaceuticals U.S.A., Inc.3$75
TG Therapeutics, Inc.3$74
Kyowa Kirin, Inc.3$73
Livanova USA, Inc.3$49
Scilex Pharmaceuticals Inc.3$48
Grifols USA, LLC2$48
Cycle Pharmaceuticals Inc2$43
Supernus Pharmaceuticals, Inc.3$43
Life Molecular Imaging Ltd2$39
Acorda Therapeutics, Inc2$38
SK Life Science, Inc.1$35
Avion Pharmaceuticals2$35
Neurocrine Biosciences, Inc.2$34
Strongbridge US Inc.2$33
Azurity Pharmaceuticals, Inc.2$30
Arbor Pharmaceuticals, Inc.2$26
Sumitomo Pharma America, Inc.1$26
Upsher-smith Laboratories LLC1$26
Axsome Therapeutics, Inc.1$24
Mallinckrodt Hospital Products Inc.1$21
Xeris Pharmaceuticals, Inc.1$20
Sanofi-aventis U.S. LLC1$18
Medtronic1$14
Assertio Therapeutics, Inc.1$14
Akcea Therapeutics, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,767 in reported general payments places this provider in the 65th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$324,454
Medicare patients
886
Services billed
6,946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BetaseronInterferon Beta-1b13$125,101
UbrelvyUbrogepant49$100,167
Nurtec OdtRimegepant Sulfate41$76,738
AustedoDeutetrabenazine13$62,184
Aimovig AutoinjectorErenumab-Aooe38$49,612
RytaryCarbidopa/Levodopa14$23,241
FycompaPerampanel16$15,946
Carbidopa-LevodopaCarbidopa/Levodopa297$10,944
Memantine Hcl392$10,444
Levetiracetam245$8,399
Donepezil Hcl509$5,160
Rivastigmine31$4,936
Primidone117$4,813
Oxcarbazepine37$4,160
Pregabalin120$2,751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$2,085$100,16749 claims
PfizerNurtec Odt$377$76,73841 claims
Teva Pharmaceuticals USA, Inc.Austedo$231$62,18413 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$320$24,84639 claims
Eisai Inc.Fycompa$150$15,94616 claims
Upsher-smith Laboratories LLCTopiramate$26$1,373144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,434 neurology providers in Florida.

Other neurology in Lake Mary

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →